ZIOPHARM Oncology, Inc. (ZIOP) Reports In-Line Q1 Loss

ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) reported Q1 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on ZIOPHARM Oncology, Inc. (ZIOP) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Marvell (MRVL) PT Raised to $225 at TD Cowen
• GLJ Research on Sell Rated Tesla (TSLA): 'We now see FSD as the main reason TSLA’s stock will bleed lower this year'